Viridian Therapeutics Q3 2023 EPS $(1.09) Down From $(0.86) YoY, Revenue $72K Misses $101.417K Est.
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics reported a Q3 2023 EPS of $(1.09), a decrease from $(0.86) in the same quarter last year. Revenue for the quarter was $72K, which did not meet the estimated $101.417K.
November 13, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viridian Therapeutics' Q3 2023 earnings report showed a larger loss per share and a revenue miss, which may negatively impact investor sentiment and the stock price in the short term.
The reported increase in loss per share and missed revenue expectations are typically seen as negative indicators by investors, which can lead to a decrease in stock price. Given that this is a quarterly earnings report, it is highly relevant and important for investors. The confidence in this analysis is high due to the direct correlation between earnings reports and stock performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100